Exemption of the Advanced Research Projects Agency for Health (ARPA-H) From Policies and Requirements of the National Institutes of Health (NIH), 19157 [2023-06620]
Download as PDF
Federal Register / Vol. 88, No. 61 / Thursday, March 30, 2023 / Notices
investigation, and must certify that a
true and complete copy of the petition
has been served upon the patent
applicant. (See H. Rept. 857, part 1, 98th
Cong., 2d sess., pp. 41–42, 1984.)
Petitions should be in the format
specified in 21 CFR 10.30.
Submit petitions electronically to
https://www.regulations.gov at Docket
No. FDA–2013–S–0610. Submit written
petitions (two copies are required) to the
Dockets Management Staff (HFA–305),
Food and Drug Administration, 5630
Fishers Lane, Rm. 1061, Rockville, MD
20852.
Dated: March 23, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023–06580 Filed 3–29–23; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Exemption of the Advanced Research
Projects Agency for Health (ARPA–H)
From Policies and Requirements of the
National Institutes of Health (NIH)
Advanced Research Projects
Agency for Health, Department of
Health and Human Services.
ACTION: Notice.
AGENCY:
The Secretary of the U.S.
Department of Health and Human
Services (HHS) has statutory authority
to exempt the Advanced Research
Projects Agency for Health (ARPA–H)
from certain policies and requirements
of the National Institutes of Health
(NIH) as necessary and appropriate to
ensure ARPA–H can most effectively
achieve its statutorily specified goals.
Pursuant to such authority, and for the
reasons stated herein, the Secretary is
giving notice that he intends to exempt
ARPA–H from all NIH policies and
requirements subject to the limitations
and condition stated herein.
FOR FURTHER INFORMATION CONTACT:
Thomas Libert, 240–731–3874,
tom.libert@arpa-h.gov.
SUPPLEMENTARY INFORMATION: This
notice follows 87 FR 32174, published
on May 24, 2022. The Consolidated
Appropriations Act, 2023 (Public Law
117–328, enacted on December 29,
2022) includes authorizing language for
ARPA–H. Notably, section 499A of the
Public Health Service Act (PHSA), as
added by section 2331(a) of the
Consolidated Appropriations Act, 2023,
establishes ARPA–H within NIH and
provides that the Director, ARPA–H,
shall report to the Secretary of HHS.
Subparagraph (A) of section
499A(a)(3) provides that the Secretary
lotter on DSK11XQN23PROD with NOTICES1
SUMMARY:
VerDate Sep<11>2014
17:22 Mar 29, 2023
Jkt 259001
may exempt ARPA–H from NIH policies
and requirements that are in effect on
the day before the enactment of section
499A as necessary and appropriate to
ensure ARPA–H can most effectively
achieve its statutorily specified goals,
except as otherwise provided for in
section 499A and subject to the
requirements of subparagraph (B).
Subparagraph (B) of section 499A(a)(3)
provides that not later than 90 days after
the date of enactment of section 499A,
the Secretary shall publish a notice in
the Federal Register describing the
specific NIH policies and requirements
from which the Secretary intends to
exempt ARPA–H, including a rationale
for such exemptions.
Pursuant to section 499A(a)(3) of the
PHSA, notice is hereby given that I
intend to exempt ARPA–H from all
policies and requirements of the NIH
that were in effect on the day before the
enactment of section 499A, that is, on
December 28, 2022.
The exemption is necessary and
appropriate to ensure ARPA–H can most
effectively achieve its statutorily
specified goals and consistent with prior
actions for the following reasons:
• The mission of ARPA–H is
complementary to NIH, but its business
model is distinct and separate. To
succeed at its mission to realize
transformative health solutions, ARPA–
H must establish a unique culture and
distinct and separate business and
operations processes, including its own
policies and requirements.
• On April 15, 2022, I transferred
ARPA–H to NIH as authorized by title
II of division H of the Consolidated
Appropriations Act, 2022 (Pub. L. 117–
103, enacted on March 15, 2022) and
delegated to the Director, NIH, certain
authorities for the purpose of carrying
out ARPA–H (87 FR 23526). As a
condition of the delegation, I specified
that NIH may not subject ARPA–H to
NIH policies.
• As noted, section 499A of the PHSA
establishes ARPA–H within NIH and
provides that the Director, ARPA–H,
shall report to the Secretary. In the Joint
Explanatory Statement (168 Cong. Rec.
S8895, 2022), Congress signaled its
intent for ARPA–H to establish its own
culture, procedures, and policies:
The agreement strongly encourages HHS to
collaborate with the Defense Advanced
Research Projects Agency (DARPA) to
develop the foundational policies,
procedures, and staff training for ARPA–H
employees. The agreement believes ARPA–H
will require a very different culture and
mission than NIH’s other 27 Institutes and
Centers.
ARPA–H shall continue to be subject
to all policies and requirements of HHS.
PO 00000
Frm 00107
Fmt 4703
Sfmt 4703
19157
All major policy, programmatic, and
operational decisions proposed by
ARPA–H shall continue to come to the
Secretary for approval.
The exemption is subject to the
following condition:
• Where ARPA–H identifies a need to
develop a policy or requirement to
fulfill its mission, it shall rely upon NIH
policies and requirements until such
time as ARPA–H develops its own
policies and requirements as
appropriate.
Xavier Becerra,
Secretary of Health and Human Services.
[FR Doc. 2023–06620 Filed 3–29–23; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Fellowships: Oncology.
Date: April 27, 2023.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Rockledge II, 6701 Rockledge Drive,
Bethesda, MD 20892 (Virtual Meeting).
Contact Person: Nywana Sizemore, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6189,
MSC 7804, Bethesda, MD 20892, 301–408–
9916, sizemoren@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
E:\FR\FM\30MRN1.SGM
30MRN1
Agencies
[Federal Register Volume 88, Number 61 (Thursday, March 30, 2023)]
[Notices]
[Page 19157]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-06620]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Exemption of the Advanced Research Projects Agency for Health
(ARPA-H) From Policies and Requirements of the National Institutes of
Health (NIH)
AGENCY: Advanced Research Projects Agency for Health, Department of
Health and Human Services.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Secretary of the U.S. Department of Health and Human
Services (HHS) has statutory authority to exempt the Advanced Research
Projects Agency for Health (ARPA-H) from certain policies and
requirements of the National Institutes of Health (NIH) as necessary
and appropriate to ensure ARPA-H can most effectively achieve its
statutorily specified goals. Pursuant to such authority, and for the
reasons stated herein, the Secretary is giving notice that he intends
to exempt ARPA-H from all NIH policies and requirements subject to the
limitations and condition stated herein.
FOR FURTHER INFORMATION CONTACT: Thomas Libert, 240-731-3874,
h.gov">[email protected]h.gov.
SUPPLEMENTARY INFORMATION: This notice follows 87 FR 32174, published
on May 24, 2022. The Consolidated Appropriations Act, 2023 (Public Law
117-328, enacted on December 29, 2022) includes authorizing language
for ARPA-H. Notably, section 499A of the Public Health Service Act
(PHSA), as added by section 2331(a) of the Consolidated Appropriations
Act, 2023, establishes ARPA-H within NIH and provides that the
Director, ARPA-H, shall report to the Secretary of HHS.
Subparagraph (A) of section 499A(a)(3) provides that the Secretary
may exempt ARPA-H from NIH policies and requirements that are in effect
on the day before the enactment of section 499A as necessary and
appropriate to ensure ARPA-H can most effectively achieve its
statutorily specified goals, except as otherwise provided for in
section 499A and subject to the requirements of subparagraph (B).
Subparagraph (B) of section 499A(a)(3) provides that not later than 90
days after the date of enactment of section 499A, the Secretary shall
publish a notice in the Federal Register describing the specific NIH
policies and requirements from which the Secretary intends to exempt
ARPA-H, including a rationale for such exemptions.
Pursuant to section 499A(a)(3) of the PHSA, notice is hereby given
that I intend to exempt ARPA-H from all policies and requirements of
the NIH that were in effect on the day before the enactment of section
499A, that is, on December 28, 2022.
The exemption is necessary and appropriate to ensure ARPA-H can
most effectively achieve its statutorily specified goals and consistent
with prior actions for the following reasons:
The mission of ARPA-H is complementary to NIH, but its
business model is distinct and separate. To succeed at its mission to
realize transformative health solutions, ARPA-H must establish a unique
culture and distinct and separate business and operations processes,
including its own policies and requirements.
On April 15, 2022, I transferred ARPA-H to NIH as
authorized by title II of division H of the Consolidated Appropriations
Act, 2022 (Pub. L. 117-103, enacted on March 15, 2022) and delegated to
the Director, NIH, certain authorities for the purpose of carrying out
ARPA-H (87 FR 23526). As a condition of the delegation, I specified
that NIH may not subject ARPA-H to NIH policies.
As noted, section 499A of the PHSA establishes ARPA-H
within NIH and provides that the Director, ARPA-H, shall report to the
Secretary. In the Joint Explanatory Statement (168 Cong. Rec. S8895,
2022), Congress signaled its intent for ARPA-H to establish its own
culture, procedures, and policies:
The agreement strongly encourages HHS to collaborate with the
Defense Advanced Research Projects Agency (DARPA) to develop the
foundational policies, procedures, and staff training for ARPA-H
employees. The agreement believes ARPA-H will require a very
different culture and mission than NIH's other 27 Institutes and
Centers.
ARPA-H shall continue to be subject to all policies and
requirements of HHS. All major policy, programmatic, and operational
decisions proposed by ARPA-H shall continue to come to the Secretary
for approval.
The exemption is subject to the following condition:
Where ARPA-H identifies a need to develop a policy or
requirement to fulfill its mission, it shall rely upon NIH policies and
requirements until such time as ARPA-H develops its own policies and
requirements as appropriate.
Xavier Becerra,
Secretary of Health and Human Services.
[FR Doc. 2023-06620 Filed 3-29-23; 8:45 am]
BILLING CODE 4140-01-P